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ABSTRACT
Prosthetic joint infections are difﬁcult to eradicate,
and antibiotic and surgical treatment strategies
lack standardisation. The present study followed
29 patients (median age 72 years, median Ameri-
can Society of Anesthesia score of two) with early
prosthetic joint infections. Treatment consisted
of device retention, surgical debridement and
therapy with rifampicin and ciproﬂoxacin for
3 months. This treatment regimen failed in ﬁve
patients during the study, with a median obser-
vation period of 674 days. The results of this
study conﬁrm the ﬁndings of the only previous
study on device retention with antibiotic
treatment.
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Infections of orthopaedic prostheses can be a
devastating experience for patients and surgeons
alike, and greatly increase the morbidity and costs
associated with joint replacement surgery [1]. The
incidence of such infections has declined steadily
[2] and should not exceed 1–2%. However,
absolute numbers have been less affected, as the
number of procedures performed has increased
greatly [3]. There is no general consensus on the
management of such patients, and there is an
absence of adequate clinical studies. Although
small in terms of the number of patients enrolled,
the study of Zimmerli et al. [4] showed that
revision surgery without removal of the pros-
thesis, combined with treatment for 3 months
(hip replacements) or 6 months (knee replace-
ments) with rifampicin and ciproﬂoxacin, yielded
increased cure rates, compared with revision
surgery and ciproﬂoxacin monotherapy, for early
manifestation (< 3 months after surgery) implant
infections. The time of manifestation of infection
is of particular importance. The prospects for a
cure without removal of the prosthesis are
reduced greatly for infections with delayed
(> 3 months to < 2 years after surgery) or late
(> 2 years after surgery) manifestations [5,6]. The
aim of the present study was to examine whether
the results obtained by Zimmerli et al. [4] could be
reproduced outside the setting of a randomised
controlled study.
Twenty-nine consecutive patients with pros-
thetic joint infection, diagnosed within 3 months
of implant surgery, were enrolled in the study
between September 2000 and June 2003. Infections
following total hip and knee replacements, inser-
tions of hemi-prostheses, and revision arthropla-
sties were included. Fixation device infections
were excluded. The American Society of Anesthe-
sia score was used as a measure of co-morbidity.
Patients (Table 1) were assessed upon enrolment,
and after 3, 12 and, if possible, ‡ 24 months. The
CDC deﬁnition for deep incisional surgical site
infection with an implant was used [7]. Treat-
ment failure was deﬁned as the presence of local
signs of infection, radiological signs of infection,
peripheral white cell counts of > 11 · 109 ⁄mL
and C-reactive protein levels of > 7 mg ⁄mL.
Microbial isolates were identiﬁed using standard
techniques [8]. Primary rifampicin resistance in
staphylococci is exceedingly rare in Norway, and
rifampicin susceptibility testing was thus not
performed.
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Aggressive soft tissue revision included exci-
sion of devitalised tissue, irrigation and exchange
of modular prosthesis components. Gentamicin-
containing ﬂeece pads were inserted before
wound closure. Between three and six biopsies
were sampled for microbiological cultures. Intra-
venous dicloxacillin, 1000 mg four-times-daily,
was started at surgery if infection was suspected,
and was continued until inclusion, 3–7 days post-
surgery. At enrolment, treatment was changed to
rifampicin, 450 mg twice-daily, and ciproﬂoxacin,
500 mg twice-daily, and was continued for
3 months, regardless of the site of infection or
surgical procedure.
A signiﬁcant pathogen was cultured from sam-
ples collected during surgery from 23 of the 29
patients. Isolates and types of infections are sum-
marised in Table 1. Failure of treatment, according
to the replacement procedure and the time interval,
is shown in Table 2. Two patients experienced
serious nausea with weight loss, but did not
discontinue treatment. One patient refused medi-
cation after 8 weeks because of nausea; no alter-
native antibiotics were commenced. These three
patients were not considered to be treatment
failures, and in this study of early manifestation
prosthetic joint infections, with a median observa-
tion time of 674 days, treatment failure occurred in
only ﬁve (17%) patients. No failures occurred in
patients with knee prostheses. One revision ar-
throplasty was considered to be a treatment failure
after 217 days; the other four treatment failures
were diagnosedwithin 122 days (median 47 days).
The treatment used in the present study was
modiﬁed from the protocol of Zimmerli et al. [4], in
that a lower dose of ciproﬂoxacin was used
(500 mg twice-daily, which is the standard dose
at this institution), compared with 750 mg twice-
daily. In addition, gentamicin-containing ﬂeece
pads were inserted before wound closure in the
present study, and a shorter treatment course was
used for infected knee prostheses (3 months com-
pared with 6 months). Although infected knee
prostheses have traditionally been considered
more difﬁcult to cure [9], there is neither strong
clinical evidence, nor in-vitro evidence, to favour
the longer 6-month period of therapy. The post-
operative intravenous course of dicloxacillin was
also shortened from 14 days to 3–7 days before
switching to rifampicin and ciproﬂoxacin oral
therapy. Concerns over poor gastrointestinal
absorption at 3 days following non-abdominal
surgery appear not to bewarranted, and rifampicin
and ciproﬂoxacin have very good bioavailability
with oral intake. Thesemodiﬁcations did not affect
the outcome adversely compared with the previ-
ous study. Anothermajor differencewas the exclu-
sion of ﬁxation device infections from the present
study. These infections can be cured by removal of
the ﬁxation device when bone stability is achieved,
and represent a different type of problem.
The success of the treatment in the present
study relied on three factors: (1) selection of early
manifestation prosthetic joint infections; (2)
adequate surgical debridement; and (3) rifampi-
cin-containing antibiotic therapy. Although all
three factors are probably of importance, their
relative signiﬁcance has not been determined.
Importantly, very elderly patients, and patients
with signiﬁcant co-morbidity, were included in
Table 1. Characteristics of pros-
thetic implant patients with infec-
tions who were included in the
study
All n = 29
Total hip
prostheses
n = 12
Hemi-
prostheses
n = 8
Knee
prostheses
n = 6
Revision
arthroplasties
n = 3
Median age, years (range) 73 (54–85) 66 (54–82) 77 (73–85) 67 (58–79) 64 (61–75)
Gender (male ⁄ female) 13 ⁄ 16 7 ⁄ 5 3 ⁄ 5 3 ⁄ 3 0 ⁄ 3
Median time in days from implant
to infection (range)
18 (8–94) 21 (12–94) 16 (11–79) 33 (14–77) 11 (8–20)
Median ASA score (range) 2 (1–4) 2 (1–3) 2 (2–4) 2 (1–3) 2 (1–3)
Microbial isolates (n)
Staphylococcus aureus 18 4 6 5 3
Staphylococcus epidermidis 4 3 1 – –
Corynebacterium JK 1 1 – – –
No isolate 6 4 1 1 –
ASA, American Society of Anesthesia.
Table 2. Treatment failures listed according to type of
procedure
Failures ⁄ total
patients
Time to failure
(days)
Knee replacement 0 ⁄ 6 –
Total hip replacement 1 ⁄ 12 122
Hemi-arthroplasty 3 ⁄ 8 41, 43, 47
Revision arthroplasty 1 ⁄ 3 217
Total 5 ⁄ 29 47 (41–217)a
aMedian (range).
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the study, indicating that the treatment protocol is
applicable for most clinical situations.
The biological rationale for including rifampi-
cin in the treatment of prosthetic device infec-
tions has been reviewed previously [10–12]. Its
excellent bioavailability with oral intake reduces
the need to remain in hospital, and helps mini-
mise the complications and costs associated with
long-term intravenous therapy. The main role of
an accompanying antibiotic is to protect against
the development of rifampicin resistance, which
occurs readily as a result of a single point
mutation. Ciproﬂoxacin is a rational choice, given
its good activity against Staphylococcus aureus,
excellent oral absorption, and activity against
adherent bacteria [13]. However, the use of
rifampicin on a routine basis for all orthopaedic
prosthetic joint infections should be discouraged.
Rifampicin is a valuable antibiotic, but has been
shown to be effective only in early-onset
infections; late-onset infections cannot usually
be eradicated without prosthesis removal [6].
In conclusion, low failure rates were achieved
following early manifestation orthopaedic pros-
thetic joint infections, without prosthesis removal,
when thorough debridement was followed by
treatment for 3 months with oral rifampicin and
ciproﬂoxacin. The success rates obtained were
comparable to those achieved in the only pub-
lished randomised controlled trial concerning
these infections. The proposed strategy for man-
agement of early manifestation implant infections
seems, therefore, to be an effective and safe option.
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ABSTRACT
During a 6-year observational study, 122 cases of
hepatitis A virus (HAV) infection were detected
in Bologna, Italy, with a c. 300% increase in cases
between 1999 and 2004. There were 104 cases
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